Studies on the anticancer drug CB10-277
Author Information
Author(s): B.J. Foster, D.R. Newell, J. Carmichael, A.L. Harris, L.A. Gumbrell, M. Jones, P.M. Goodard, A.H. Calvert
Primary Institution: Institute of Cancer Research and Royal Marsden Hospital
Hypothesis
CB10-277 has similar antitumor activity to dacarbazine in preclinical models and patients.
Conclusion
CB10-277 showed antitumor activity in patients with melanoma and sarcoma, although nausea and vomiting were significant side effects.
Supporting Evidence
- CB10-277 showed a similar spectrum and level of activity compared to dacarbazine in preclinical models.
- Nausea and vomiting were dose-limiting toxicities observed in the Phase I trial.
- Responses were noted in patients with melanoma, sarcoma, and carcinoid.
- Pharmacokinetics indicated that the AUC of CB10-277 increased linearly with dose.
Takeaway
CB10-277 is a new cancer drug that can help some patients with melanoma and sarcoma, but it can also make them feel sick.
Methodology
The study involved preclinical models and a Phase I trial with pharmacokinetics assessed in patients.
Limitations
The study had a small sample size and was limited to specific cancer types.
Participant Demographics
Median age was 44 years, with 12 females and 24 males.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website